Health Net's coverage of Biodesix's proteomic test for non-small cell lung cancer follows similar decisions last month by Aetna and Cigna.
OKP will pay for testing if standard first trimester screening indicates a risk higher than 1:1000 for trisomies 21, 18, or 13.
Aetna is the first major commercial insurer to cover Interpace's ThyGenX and brings the total number of covered lives for it to more than 100 million.
The test differentiates benign thyroid nodules from cancerous ones.
The company has received similar coverage decisions from other payors in recent months.
The decision means that UnitedHealthcare's members will have access to Biodesix's test for advanced NSCLC as a covered benefit.
Personalized medicines haven't been a big part of APMs to date, but the report suggests ways in which payment models might be structured to spur utilization.
About 19 million ACPN members will now have access to Cancer Genetics' cancer diagnostic services through their insurers.
The noninvasive colorectal cancer screening test will now be available to more than one million people in Massachusetts and Rhode Island.
In an update medical policy, Anthem said it will cover the test every three years for certain patients for whom the test is considered medically necessary.
According to Gizmodo, researchers have developed a list of a million nucleic acid-like polymers that could store genetic information.
An opinion piece in the Washington Post argues that golden rice could save the sight and lives of many children.
US National Institutes of Health has issued a new draft data-sharing policy, ScienceInsider reports.
In Cell this week: analysis of immune microenvironment in hepatocellular carcinoma, proteogenomic analysis of clear cell renal cell carcinoma, and more.